ArticleFrontiers in oncology2025
Construction and validation of a simple, scoreable model for predicting infection risk in patients with multiple myeloma: a retrospective single-center study.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: This study aims to identify the risk factors for infection in patients with multiple myeloma (MM) and to develop a predictive model for infection. Methods: We retrospectively analyzed the clinical data of 180 multiple myeloma patients with MM who underwent chemotherapy at the First Affiliated Hospital of Jishou University from January 2017 to December 2022. A predictive model for infection events was constructed based on these data. Results: In the modeling group, 34 out of 90 patients (37.78%) experienced infections, whereas in the validation group, 40 out of 90 patients (44.44%) had infections. Binary logistic regression analysis showed that the levels of C-reactive protein level, fasting blood glucose level, lactate dehydrogenase level, Eastern Cooperative Oncology Group (ECOG) score, and the percentage of bone marrow plasma cell percentage were independent risk factors for infection in patients with MM (P < 0.05). The infection prediction model developed using these variables demonstrated good accuracy, with an area under the ROC curve of 0.827 (95% CI: 73.66%-91.78%) in the modeling group and for the validation group being 0.760 (95% CI: 65.97%-85.93%) in the validation group. Conclusion: This study confirms that C-reactive protein level, fasting blood glucose level, lactate dehydrogenase level, ECOG score, and the percentage of bone marrow plasma cell percentage are significant risk factors for infection in patients with MM. Clinical significance: This infection prediction model offers substantial clinical value by enabling a shift from reactive management to proactive, preventive intervention for infections in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.